CBLN3

Across TCGA pan-cancer cohorts, CBLN3 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of CBLN3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CBLN3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CBLN3 is over-expressed in tumor, although a few such as UCEC and KICH show the opposite, repressed pattern.

KIRC, HNSC, and UCEC are the cancer types where CBLN3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CBLN3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+1.309	<.001	11	view →
HNSC	Female	III,IV	+0.740	.002	7	view →
UCEC	All	All	−1.117	<.001	6	view →
KICH	All	All	−0.775	<.001	6	view →
LUAD	All	All	+0.207	.023	3	view →
BLCA	Male	III,IV	−0.841	.018	2	view →
LUSC	All	All	−0.301	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

CBLN3–KIRC

Open the KIRC breakdown →